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Abstract
Background: The molecular epidemiology of HIV-1 in the Caribbean has been described using partial genome sequencing;
subtype B is the most common subtype in multiple countries. To expand our knowledge of this, nearly full genome
amplification, sequencing and analysis was conducted.
Methodology/Principal Findings: Virion RNA from sera collected in Haiti, Dominican Republic, Jamaica and Trinidad and
Tobago were reverse transcribed, PCR amplified, sequenced and phylogenetically analyzed. Nearly full genomes were
completed for 15 strains; partial pol was done for 67 strains. All but one of the 67 strains analyzed in pol were subtype B; the
exception was a unique recombinant of subtypes B and C collected in the Dominican Republic. Of the nearly full genomes
of 14 strains that were subtype B in pol, all were subtype B from one end of the genome to the other and not inter-subtype
recombinants. Surprisingly, the Caribbean subtype B strains clustered significantly with each other and separate from
subtype B from other parts of the pandemic.
Conclusions: The more complete analysis of HIV-1 from 4 Caribbean countries confirms previous research using partial
genome analysis that the predominant subtype in circulation was subtype B. The Caribbean strains are phylogenetically
distinct from other subtype B strains although the biological meaning of this finding is unclear.
Citation: Nadai Y, Eyzaguirre LM, Sill A, Cleghorn F, Nolte C, et al. (2009) HIV-1 Epidemic in the Caribbean Is Dominated by Subtype B. PLoS ONE 4(3): e4814.
doi:10.1371/journal.pone.0004814
Editor: Landon Myer, University of Cape Town, South Africa
Received June 24, 2008; Accepted February 4, 2009; Published March 12, 2009
Copyright:  2009 Nadai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by 1R21 A1057084-02 from the National Institute of Allergy and Infectious Disease (PI: F Cleghorn, then WA Blattner) and also
by the ‘‘Institute of Human Virology, University of Maryland, Baltimore, AITRP in Brazil, Caribbean and Nigeria’’, NIH grant # 5K43TW001041. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jecarr@ihv.umaryland.edu
Introduction
The Caribbean has the second highest HIV-1 prevalence in the
world today, approximately 1% in adult men and women,
exceeded only by sub-Saharan Africa [1]. There is quite a bit of
variability between the different countries in the Caribbean,
however. The national adult HIV prevalence rate exceeds 1% in
Barbados, Dominican Republic, Jamaica and Suriname, 2% in the
Bahamas, Guyana and Trinidad and Tobago, and is greater than
3% in Haiti.
The various epidemics in the Caribbean are driven predomi-
nantly by heterosexual intercourse, fuelled by commercial sex
work in societies with widespread poverty. A background of
stagnant tourism-dependent economies, early coitarche, high
numbers of sexual partners for both sexes, high rates of sexually
transmitted diseases, stigmatization and discrimination against
sexual minorities are some of the many factors driving the
Caribbean HIV-1 epidemic [2,3,4]. Homosexual intercourse is a
minor factor in most of the epidemics, though the extent of its
contribution is probably underestimated due to stigma. Injecting
drug use drives the epidemics in only two locations: Bermuda and
Puerto Rico [4].
Although international efforts to systematically collect, charac-
terize, and classify HIV isolates from around the world have
increased considerably, data on HIV-1 genetic variations in the
Caribbean remains limited. Globally, nine subtypes and 34
circulating recombinant forms have been defined in HIV-1 Group
M, which accounts for most of the HIV-1 pandemic. One of the
earliest HIV-1 strains characterized by full-genome sequencing
(RF) was from a Haitian woman living in the United States
but since that time no full genomes have been sequenced
to represent the epidemic(s) in the Caribbean [5]. Partial genome
sequencing of viruses from multiple Caribbean islands have
reported subtype B as virtually the only subtype present (with
the exception of Cuba) [6–8]. Because subtype B is the most
common subtype in the United States, its presence in the
Caribbean would seem unremarkable, but in fact subtype B has
never been the most common subtype in a heterosexual epidemic
anywhere in the world [9]. As such, the epidemics in the
Caribbean are unique.
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4814The effort to more fully characterize the subtypes in circulation
around the Caribbean was initiated by an examination of the
viruses from HIV-positive patients from four countries: Dominican
Republic (DO), Haiti (HT), Jamaica (JM) and Trinidad and
Tobago (TT). The nearly full-length genomes of HIV-1 were
amplified from the viral RNA and sequenced and represent the
first nearly full-length sequences of HIV-1 from the Dominican
Republic and Jamaica and the first in over a decade from Haiti
and Trinidad and Tobago. To evaluate the genetic distribution
pattern of HIV-1 in the Caribbean region, we analyzed
phylogenetic relationships and genetic variability among HIV-1
strains isolated from patient samples collected between 2000 and
2005 in seroprevalence studies in Trinidad and Tobago, Jamaica,
Haiti, and the Dominican Republic.
Materials and Methods
Study Subjects
Blood samples were drawn from patients attending the following
centers: GHESKIO in Port-au-Prince, Haiti; Ministry of Health,
Kingston, Jamaica; IDCP, Santo Domingo, Dominican Republic;
Medical Research Foundation of Trinidad and Tobago, Port of
Spain, Trinidad and Tobago. Patients were newly diagnosed as
HIV(+) and had been infected for an unknown period of time.
Serum was collected, frozen and sent to IHV, Baltimore, MD for
analysis. All patients gave written informed consent and the study,
including the notification of the subjects of their HIV status, was
approved by the IRB of the University of Maryland, Baltimore,
and the local participating institutions.
Reverse Transcription and Amplification
The methods for RNA extraction, reverse transcription (RT),
polymerase chain reaction (PCR) and the primers used for the
nearly full-length PCR amplification have been previously
described [10,11]. Briefly, RNA was extracted from 140 mlo f
serum concentrated from 500 ml, using QIAamp Viral RNA Mini
Assay (Qiagen, Valencia, CA). Reverse transcription of RNA was
performed using SuperScript
TM III RNase H
2 Reverse Tran-
scriptase (Invitrogen, Carlsbad, CA) with RT3474R and UN-
INEF79 primers for the partial pol region and the nearly full-length
genome amplification, respectively. cDNA synthesized with
UNINEF79 as primer was used as template for the nearly full-
length PCR amplification with limiting-dilution methods [11].
This method utilizes one, two or three overlapping amplicons to
cover most of the HIV genome, from 795 to 9180 on HXB-2
(Genbank Accession No. K03455) and is routinely successful with
well preserved serum having a viral load of 10
5 or greater. The
amplicon does not, however, include the U5, R or U3 components
of the viral RNA.
Specifically, reverse transcription of the RNA was performed by
priming with UNINEF79 (59-GCACTCAAGGCAAGCTT-
TATTGAGGCTT-39) close to the 39 end of the viral RNA or
by VIF-VPUoutR1 (59-GGTACCCCATAATAGACTGTRA-
CCCACAA-39)i nvpu [11]. The extracted RNA (3 ml) was reverse
transcribed in a total volume of 20 ml with 500 mM dNTP,
2.5 mM primer, 16 RT buffer, 5 mM MgCl2, 10 mM DTT,
40 U RnaseOUT, and 400 U SuperScript
TM III RNase H
2
RT (Invitrogen, Carlsbad, CA). The RNA, primer and dNTPs
were first incubated at 65uC for 5 minutes, then the remaining
reagents were added for cDNA synthesis at 50uC for 2 hours,
followed by 85uC for 5 minutes. Then 2 U E. coli RNase H
(Invitrogen, Carlsbad, CA) was added, and the reaction tubes were
incubated at 37uC for 20 minutes followed by 70uC for
15 minutes.
Two or three regions of the viral genome were independently
amplified from the cDNA to contain a nearly full-length genome
of HIV-1. The two-amplicon strategy consisted of one amplicon of
about 2.6-kb consisting of gag and part of pol (nts 769-3338 HXB-2
(Genbank Acc No: K03455)) and another amplicon of approxi-
mately 7.0-kb stretching from the 59 end of pol to the middle of nef
(nts 2143–9181 HXB-2). A three-amplicon strategy was used as
needed. The first amplicon was the gag-pol amplicon described
above, the second spanned pol to vpu (nts 2483–6231 HXB-2) and
the third env to nef (nts 5861–9181 HXB-2). The reaction volume
was 50 ml, containing 16 PCR buffer, 350 mM dNTP mixture,
0.4 mM of each primer and 5 U Expand Long Template PCR
enzyme mixture (Roche Diagnostics, Indianapolis, IN). Cycling
conditions for the first round were: 94uC for 2 minutes and then
10 cycles of (94uC1 0s ,6 0 uC3 0s ,6 8 uC 3 min), then 20 cycles of
(94uC1 0 s ,5 5 uC3 0 s ,6 8 uC 3 min) followed by 68uC for
10 minutes. For the second round, cycling conditions were the
same, except that the annealing temperature for the first 10 cycles
was 65uC and the incubation at 68uC was for 8 minutes.
The products of reverse transcription with the primer RT3474R
were employed for amplification of the partial pol region. The first-
round amplification was done with 2 primers: Pro5F (59-
AGAAATTGCAGGGCCCCTAGGAA) and RT3474R (59-
GAATCTCTCTGTTTTCTGCCAG), using AmpliTaq Gold
(Applied Biosystems, Foster City, CA) and 2 mM of MgCl2 in a
total volume of 50 mL. The second-round amplification was
completed using the following 2 primers: Pro3F (59-AGANCA-
GAGCCAACAGCCCCACCA) and ProRT (59- TTTCCCCAC-
TAACTTCTGTATGTCATTGACA). The first-round amplifi-
cation reactions began with a ‘‘hot start’’ at 95uC for 10 minutes to
activate the polymerase, followed by 30 cycles for 30 seconds at
94uC, 30 seconds at 55uC, and 1.5 minutes at 72uC, then a step at
7 minutes at 72uC was followed to end the cycles. For the second-
round amplification, the cycling conditions were the same except
for an annealing temperature of 58uC and the use of 40 cycles
instead of 30. The partial pol amplicon contained the coding
sequences for protease and part of reverse transcriptase (RT),
corresponding to nts 2167 through 3307 on HXB-2.
Amplified DNA for the partial pol and nearly full-length regions
were purified and sequenced in the Applied Biosystems 3130xl
automated sequencer using Big Dye terminators (Applied Biosys-
tems),andthesequenceswereassembledwithSequencherv4.6(Gene
CodesCorporation,AnnArbor,MI).Whenmultipleampliconswere
used, they were not merged unless the overlapping sequences were
within2%ofeachother.Nearlyfullgenomeandpartialpolsequences
were deposited in Genbank under accession numbers EU839596–
EU839610 and EU439709–EU439774, respectively.
Analysis. A multiple alignment of the newly derived
protease/RT sequences and nearly full-length genome sequences
with selected reference sequences was constructed, consisting of
1069 nts and 8364 nts, respectively. Phylogenetic trees were
generated, and the consistency of branching order was evaluated
using SEQBOOT, DNADIST, NEIGHBOR, and CONSENSE
modules of the Phylogeny Inference Package (V3.52c).
Recombinant analysis was performed with Simplot, version 3.4,
and alignment examination was used to determine precise
breakpoints [12]. After breakpoint identification, each segment
was extracted and analyzed phylogenetically to confirm the
assignment of subtype; breakpoint locations were designed
relative to HXB-2. The Kimura 2-parameter method was used
to calculate pairwise genetic distances. Analysis of the protease-RT
sequences for mutations that might lead to resistance to
antiretroviral drugs was performed using the Stanford University
Database (http://hivdb.stanford.edu/hiv).
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sequence and visually examined to identify sites that might
distinguish the Caribbean strains. The prevalence of particular
amino acids were compared between the Caribbean sequences
and reference B sequences using Fisher’s Exact Test without
correcting for multiple comparisons.
Results
A total of 67 partial pol sequences of HIV-1 from the four
Caribbean countries were analyzed: Trinidad and Tobago
(n=30), Dominican Republic (n=18), Haiti (n=16) and Jamaica
(n=3). Phylogenetic analysis classified 66 partial pol sequences as
HIV-1 subtype B and one, from the Dominican Republic, as a
recombinant between subtypes B and C (Figure 1). Based on the
genetic analysis, some of the Trinidad samples were probably
epidemiologically linked but aside from those clusters there was no
clustering within Caribbean subtype B by country, island or
language.
Of the 67 samples with partial pol sequences, 15 specimens were
also successfully amplified for the nearly full-length genome from
serum RNA. The 15 that underwent full-length analysis consisted
of the one non-B and those that produced full length ampicons
readily. Previous experience with the primers suggests that failure
to amplify was not due to primer mismatch, but rather to sample
quality. Fourteen strains were non-recombinant subtype B; all
strains were analyzed for evidence of intersubtype recombination
and none was observed. The nearly full-length sequence of the B/
C recombinant strain revealed that it was a unique recombinant
form which was subtype B in protease and the amino terminus of
RT, while the rest of the genome was subtype C. The sequence did
not cluster with CRF31_BC or any other B/C recombinant in
genbank.
When analyzed with other subtype B strains from the pandemic,
the 14 nearly full-length sequences of the subtype B strains from
the Caribbean clustered together significantly with a bootstrap
value of 82% (Figure 2). The only ‘non-Caribbean’ subtype B was
RF, a virus collected from an Haitian woman in the United States
[5]. Aside from one cluster between two of the Trinidad samples
there was no significant clustering within the Caribbean strains,
either by country, island or language. Analysis of the nine genes of
HIV-1 for mutations more common in the Caribbean strains than
in subtype B reference strains revealed a handful of sites that
significantly distinguished the two populations (Table 1).
Analysis of the protease/RT sequences revealed a lack of major
drug resistance-conferring mutations among the Caribbean HIV-
1-infected samples except for one sample from the Dominican
Republic. Tropism for co-receptor usage of HIV-1 was deter-
mined in silico for 22 partial env sequences from the study
population. The PSSM procedure was used to predict the
phenotype [13]. Only 2 out of the 22 sequences had a preference
for CXCR4 rather than CCR5, both of them from the Dominican
Republic.
Figure 1. Phylogenetic analysis of 67 partial pol sequences of
HIV-1 from Caribbean countries: Trinidad and Tobago (TT),
Dominican Republic (DO), Haiti (HT) and Jamaica (JM). A
neighbor-joining phylogenetic tree was built using the Kimura 2-
parameter model and significant parsimony bootstrap values (.70%)
were placed next to the nodes. The genetic distance corresponding to
the lengths of the branches is shown by the scale below the tree.
Reference samples are those named, preceded by the subtype; one of
the study samples (the B/C recombinant) is also named.
doi:10.1371/journal.pone.0004814.g001
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deletion of threonine in the V3 loop in 40% of the Caribbean
samples overall, and this was more common in samples from
Trinidad and Tobago (67%) than in the other countries, where it
ranged from 20% (JM), to 33% (DO). Overall, this mutation is
associated preferentially with the Caribbean strains (env T319-,
Table 1).
Discussion
Nearly full-length genome sequencing has been tremendously
helpful in understanding the HIV epidemics in many parts of the
world; when inter-subtype recombinants are circulating, partial
genome sequencing can be very misleading. To date, the only HIV
viral genomes collected in the Caribbean that have been fully
sequenced were from Cuba [14]. Partial genome sequencing by
many has shown that outside of Cuba the epidemic was dominated
by subtype B, the strain of HIV-1 common in the developed world
[2,6,8,15,16]. It was to improve our knowledge about the strains in
the Caribbean that nearly full genome amplification and
sequencing was performed for samples from 4 countries: Trinidad
and Tobago, Jamaica, Dominican Republic and Haiti.
Based on the sequence of the protease and RT region of pol, the
majority of strains (66/67, 98.5%) were subtype B, although one,
from the Dominican Republic, was a B/C recombinant.
Phylogenetic analysis of this region revealed no clustering of
Caribbean sequences distinct from non-Caribbean, or between
one country and another.
Analysis of the nearly full genome sequences of the 14 subtype B
strains demonstrated no evidence of inter-subtype recombination.
Of note, however, is the fact that the region of the genome that
was sequenced did not include the parts of the RNA that form the
LTR in the provirus, consequently it is still possible that the LTR
could be from a non-B subtype, although not likely. Full genome
analysis of the subtype B strains did support the distinct clustering
of the subtype B Caribbean sequences separate from those from
the pandemic, including South America. This is surprising because
there is undoubtedly a great deal of human traffic between the
U.S. and Europe, on the one hand, and the Caribbean, on the
other. In an attempt to locate the part of the genome that might be
contributing to the monophyletic clustering, a sliding window
examination of 8.5 kb revealed no specific location on the genome
that was responsible. There were, however, isolated sites that
distinguished the Caribbean strains from others. Shown in Table 1,
there were some amino acid mutations that significantly
distinguished the two populations. In comparisons such as this, it
is appropriate to consider the fact that these comparisons are being
done for each of the .3000 amino acids in the HIV-1 genome,
and thus the statistical significance should be adjusted. If that
adjustment were done, no amino acid mutations would statistically
distinguish the two populations. As an exploratory exercise,
however, it is valuable to explore where the phylogenetic signal
may be coming from. The first site, gag D102E, occurs in the
matrix protein and is associated with Elite Controllers [17].
Another Caribbean-specific mutation has already been reported:
the presence of a threonine deletion in the V3 loop of Trinidad
samples (env T319-) [8]. Most of the other changes were
conservative, and are not known to be associated with specific
phenotypic differences. These sites and others were so uncommon
that phylogenetic clustering only achieved statistical significance
when the full genome was analyzed (data not shown). It is unclear
what the biological importance of this phylogenetic distinction is
but this question could be explored in vitro.
There are two possible explanations for the phylogenetic
clustering of the Caribbean strains. The first is that it can be the
result of founder effects from when the epidemic first began that
are still detectable 20 years later. There are several arguments
against that theory: given the human traffic in and out of the
Caribbean, it is extremely unlikely that a founder effect would
continue so long. Another fact that argues against the founder
effect is that there is no clustering of samples by country or
language, as you would expect if there were different founder
Figure 2. Phylogenetic analysis of 14 nearly full genome
sequences of HIV-1 Subtype B from Caribbean countries:
Trinidad and Tobago (TT), Dominican Republic (DO), Haiti
(HT) and Jamaica (JM). Reference subtype B sequences are indicated
by the country of origin; they are: US: MN, JRCSF, SF2, WR27, P896, NY5,
BCSG3C, YU2, RF, U23487; DE: D31, HAN; GB: CAM1, study sequences
(bold) are identified by name. A neighbor-joining phylogenetic tree was
built using the Kimura 2-parameter model and significant parsimony
bootstrap values (.70%) were placed next to the nodes. The genetic
distance corresponding to the lengths of the branches is shown by the
scale below the tree.
doi:10.1371/journal.pone.0004814.g002
Table 1. Amino acid sites that differ between the Caribbean
B strains and the subtype B reference strains.
Gene Location Mutation Caribbean B Reference B p
gag (n=25) (n=19)
matrix D102E 23 11 0.01
capsid I159V 9 15 0.005
pol (n=14)
signal peptide N21TDA 8 18 0.03
protease K97R 1 13 0.0004
rev (n=14)
V102I 2 13 0.002
env (n=14)
V3 loop T319- 5 0 0.008
C5 N474D 5 15 0.01
C5 K476RM 5 17 0.002
doi:10.1371/journal.pone.0004814.t001
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be some form of consistant selection pressure on these viruses that
is not as strong in subtype B viruses from the developed world. As
mentioned earlier, the Caribbean is the only region of the world
that has a robust heterosexually-driven epidemic of subtype B. In
Thailand, South Africa and Argentina, concentrated epidemics in
high risk populations preceded generalized epidemics in the
general public. In each of these cases, subtype B was the subtype
common in the concentrated epidemic and a non-B subtype
replaced it as the epidemic grew [9,16]. Subtype B viruses from the
Caribbean may have acquired features that have enabled it to
generate a more ‘successful’ heterosexual epidemic.
The data presented here have limitations: the samples used were
not collected using any systematic sampling method and might not
adequately represent the strains in these four countries. The
number of full length genome sequences that could be performed
was limited, and the selection of those was determined by ease of
amplification, which could bring in a consistant bias against
certain strains. These primers have been used successfully for
many subtypes and the likelihood of sequence bias is not high,
however. In general, the study was limited by the small sample
size, and this would have been more consequential if the molecular
epidemiology had been more complex. The findings, however, are
consistant with the findings of others based on partial genome
sequences and this lends support to their validity.
The HIV epidemic in the Caribbean is second only to sub-
Saharan Africa in the prevalence of infection in the generalized
population [1]. The complexities of the region, with its different
islands, languages and cultures, has presented a challenge for
coordinating research activities throughout the region, difficulties
that are compounded by the low standard of living for many of the
countries. As anti-retroviral drugs are deployed across the region,
it becomes even more important to have a solid baseline
understanding of the molecular epidemiology of HIV in the
various countries, and to begin to track the emergence of drug
resistance.
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